Novo Nordisk A/S (NVO)’s Top Investor Decides to Take Control of its Board, Reports Reuters

Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo Nordisk A/S (NYSE:NVO)’s top investor, the non-profit Novo Nordisk Foundation, decided to take control of the company’s board. It vowed a strong emphasis on the critical US market to fuel sales growth for Wegovy, and highlighted the need to move faster on the mass-market channels, reported Reuters. Notably, Americans are now seeking weight-loss drugs, such as Wegovy, not from their doctors or pharmacies, but from online health platforms.Novo Nordisk A/S (NVO)’s Top Investor Decides to Take Control of its Board, Reports Reuters

Reuters further highlighted that Novo Nordisk A/S (NYSE:NVO), which initially celebrated the success of its obesity drug, has lost the market lead to the US rival Eli Lilly and cheaper copycats, amidst pressure on prices from the US President and growing direct-to-consumer sales. Markus Manns, portfolio manager at Novo shareholder Union Investment, stated that board overhaul is expected to give Novo Nordisk A/S (NYSE:NVO) more consumer-facing know-how.

Vltava Fund, an investment management company, recently released its Q3 2025 investor letter. Here is what the fund said:

“Novo Nordisk A/S (NYSE:NVO) probably needs no long introduction. It is one of Europe’s largest companies and a global leader in the treatment of two major lifestyle diseases – diabetes and obesity. The company has grown historically through the development and production of insulin and has held a dominant share of the global market in that group of products for decades. In recent years, obesity treatment has become its key growth segment. Its best-known product is Wegovy, which has proven to be highly effective in weight reduction. A smaller part of the business consists of drugs for rare diseases, particularly in the areas of hemophilia and growth hormone therapy. Novo Nordisk has highly integrated production, from molecule development to fully automated filling lines for injection pens, and global distribution to more than 170 countries, with a focus on the United States, Europe, and a rapidly growing share in Asia. Its biggest competitor is Eli Lilly, and these two companies now effectively form a duopoly in modern treatment of diabetes and obesity. Barriers to entry into the industry are extremely high, due to long development times, regulation, and enormous investments in production and distribution.

Story Continues

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.

View Comments